Prostate cancer can adapt to androgen deprivation treatment by mutating AR, amplifying/ overexpressing AR, upregulating constitutively-lively AR splice variants (AR-Vs) that lack the ligand-binding area
Androgen deprivation treatment, which disrupts androgen receptor (AR) signaling via castration or AR antagonists, is the initial-line treatment method for disseminated prostate cancer. Nevertheless, development to the presently incurable phase,…